vs
Side-by-side financial comparison of PAVmed Inc. (PAVM) and PLUS THERAPEUTICS, INC. (PSTV). Click either name above to swap in a different company.
PLUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.4M vs $996.0K, roughly 1.4× PAVmed Inc.). PAVmed Inc. runs the higher net margin — 6465.8% vs -417.9%, a 6883.7% gap on every dollar of revenue. On growth, PAVmed Inc. posted the faster year-over-year revenue change (25.9% vs -3.2%). PLUS THERAPEUTICS, INC. produced more free cash flow last quarter ($-6.3M vs $-8.9M).
PAVmed Inc. is a commercial-stage medical technology company that designs, develops and commercializes innovative diagnostic and therapeutic medical products. Its portfolio covers point-of-care diagnostics, interventional oncology and gastroenterology solutions, primarily serving healthcare providers and patients across the United States.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
PAVM vs PSTV — Head-to-Head
Income Statement — Q3 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $996.0K | $1.4M |
| Net Profit | $64.4M | $-5.7M |
| Gross Margin | -38.7% | — |
| Operating Margin | -1162.4% | -420.0% |
| Net Margin | 6465.8% | -417.9% |
| Revenue YoY | 25.9% | -3.2% |
| Net Profit YoY | 464.4% | -46.4% |
| EPS (diluted) | $1.44 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | $996.0K | $1.5M | ||
| Q2 24 | $979.0K | $1.3M | ||
| Q1 24 | $1.0M | $1.7M |
| Q4 25 | — | $-5.7M | ||
| Q3 25 | — | $-4.4M | ||
| Q2 25 | — | $5.2M | ||
| Q1 25 | — | $-17.4M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | $64.4M | $-2.9M | ||
| Q2 24 | $-10.8M | $-2.9M | ||
| Q1 24 | $-15.2M | $-3.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -38.7% | — | ||
| Q2 24 | -70.2% | — | ||
| Q1 24 | -72.7% | — |
| Q4 25 | — | -420.0% | ||
| Q3 25 | — | -320.8% | ||
| Q2 25 | — | -110.6% | ||
| Q1 25 | — | -333.9% | ||
| Q4 24 | — | -276.2% | ||
| Q3 24 | -1162.4% | -260.9% | ||
| Q2 24 | -1397.8% | -289.1% | ||
| Q1 24 | -1389.7% | -196.7% |
| Q4 25 | — | -417.9% | ||
| Q3 25 | — | -316.6% | ||
| Q2 25 | — | 370.6% | ||
| Q1 25 | — | -1643.2% | ||
| Q4 24 | — | -276.4% | ||
| Q3 24 | 6465.8% | -197.4% | ||
| Q2 24 | -1105.9% | -229.9% | ||
| Q1 24 | -1506.1% | -194.5% |
| Q4 25 | — | $0.95 | ||
| Q3 25 | — | $-0.04 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $-1.19 | ||
| Q4 24 | — | $-0.51 | ||
| Q3 24 | $1.44 | $-0.37 | ||
| Q2 24 | $-1.19 | $-0.71 | ||
| Q1 24 | $-2.62 | $-0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $765.0K | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-4.9M | $4.0M |
| Total Assets | $30.6M | $16.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $16.6M | ||
| Q2 25 | — | $6.9M | ||
| Q1 25 | — | $9.9M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | $765.0K | $4.8M | ||
| Q2 24 | $25.5M | $8.4M | ||
| Q1 24 | $25.5M | $3.2M |
| Q4 25 | — | $4.0M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $-23.6M | ||
| Q4 24 | — | $-8.9M | ||
| Q3 24 | $-4.9M | $-5.2M | ||
| Q2 24 | $-73.9M | $-7.6M | ||
| Q1 24 | $-68.8M | $-4.8M |
| Q4 25 | — | $16.3M | ||
| Q3 25 | — | $18.7M | ||
| Q2 25 | — | $10.3M | ||
| Q1 25 | — | $12.1M | ||
| Q4 24 | — | $6.6M | ||
| Q3 24 | $30.6M | $7.0M | ||
| Q2 24 | $39.4M | $11.2M | ||
| Q1 24 | $37.3M | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.9M | $-6.3M |
| Free Cash FlowOCF − Capex | $-8.9M | $-6.3M |
| FCF MarginFCF / Revenue | -892.5% | -459.9% |
| Capex IntensityCapex / Revenue | 0.6% | 2.2% |
| Cash ConversionOCF / Net Profit | -0.14× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-45.8M | $-20.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-2.5M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | $-8.9M | $-3.7M | ||
| Q2 24 | $-11.7M | $-1.1M | ||
| Q1 24 | $-13.1M | $-4.5M |
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | $-8.9M | $-3.7M | ||
| Q2 24 | $-11.7M | $-1.2M | ||
| Q1 24 | $-13.2M | $-4.6M |
| Q4 25 | — | -459.9% | ||
| Q3 25 | — | -184.3% | ||
| Q2 25 | — | -417.6% | ||
| Q1 25 | — | -583.1% | ||
| Q4 24 | — | -86.5% | ||
| Q3 24 | -892.5% | -253.7% | ||
| Q2 24 | -1190.9% | -96.2% | ||
| Q1 24 | -1302.1% | -271.5% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | 0.6% | 1.0% | ||
| Q2 24 | 0.3% | 6.3% | ||
| Q1 24 | 4.2% | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.13× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.14× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
